Bevacizumab before surgery for new high-grade brain tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether giving bevacizumab (a drug that blocks blood vessel growth) before surgery helps treat newly diagnosed high-grade gliomas. It may be an option for adults who have not had prior anti-angiogenic therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a new, high-grade brain tumor (glioma) seen on scans.
- Your daily functioning (KPS score) is at least 60 out of 100.
- You have not been treated with drugs like Avastin (bevacizumab) before.
- You do not have serious heart, lung, liver, or kidney disease.
- You have not had a blood clot in the past 6 months.
- You do not have active infections like tuberculosis or hepatitis.
- Your blood pressure is well controlled, and you have no bleeding problems or unhealed wounds.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests tislelizumab (an anti–PD-1 immune therapy) combined with low-dose bevacizumab (Avastin) for recurrent glioblastoma that has already been treated with bevacizumab. If you qualify, you may be offered a new combination approach aimed at slowing tumor growth.
This Phase 2 study tests a protective approach using bevacizumab (a medicine that blocks VEGF) while doctors carefully increase the dose in people with glioblastoma. It’s meant to help control tumor growth and possibly reduce certain risks that can happen with blood-vessel–targeting treatments.
This early-stage trial tests whether giving a targeted cancer medicine (bevacizumab) directly into brain arteries can help shrink or control certain recurrent (coming back) brain tumors. It may be an option if standard treatments are no longer working.
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
This trial tests a combination of two drugs—APG-157 (an oral plant-based medicine) and bevacizumab (Avastin)—for people with recurrent high-grade brain tumors that have already been treated with standard therapies. The goal is to see if adding APG-157 can help control the tumor better.
This trial tests a medication called bevacizumab (given as an IV infusion) to see if it can improve symptoms in people with brain arteriovenous malformations (AVMs) that cannot be treated with standard therapies. It is for those whose AVMs cause significant disability.
Hear when a new Brain Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.